# Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT03450343** · PHASE1 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 9 (actual)

## Conditions studied

- Large B-Cell Diffuse Lymphoma

## Interventions

- **DRUG:** Oral azacitidine
- **DRUG:** R-ICE

## Key facts

- **NCT ID:** NCT03450343
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-04
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-01-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450343, "Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03450343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*